Core Viewpoint - Tianyu Biological Technology Co., Ltd. has announced the use of its own funds to pay for part of the fundraising investment project and will replace it with an equivalent amount of raised funds, ensuring the smooth implementation of the project without affecting the interests of shareholders [1][8][11]. Fundraising Basic Situation - The company raised a total of RMB 402.27 million by issuing 48.35 million shares at a price of RMB 8.32 per share, with a net amount of RMB 393.87 million after deducting issuance costs [1]. Fundraising Investment Project Situation - The company adjusted its fundraising usage plan due to the net amount being less than initially planned, with the project "Tianchang Longgang Red Cultural Tourism Scenic Area Engineering General Contracting Project" extended to be operational by December 2025 [3]. Reasons and Process for Using Own Funds - The company faced difficulties in directly using raised funds for certain payments, such as wages for migrant workers, which necessitated the use of its own funds initially, followed by a replacement with raised funds [5][6]. Impact on the Company - The decision to use self-funds for part of the project payments will not affect the normal implementation of the fundraising project and will not change the direction of the raised funds or harm the interests of shareholders [8][10]. Review Procedures and Opinions - The board of directors and the supervisory board have approved the use of self-funds and the subsequent replacement with raised funds, confirming that the decision aligns with the interests of the company and shareholders [9][10].
天域生物科技股份有限公司关于使用自有资金支付募投项目部分款项并以募集资金等额置换的公告